Infectious Disease Control
HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]
* Arexvy has been approved by the Health Sciences Authority (HSA) of Singapore for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.[2] * Arexvy is 94.6% efficacious in prevent...
2024-05-16 10:00
2161
![HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1]](https://mma.prnasia.com/media2/2412228/GSK_Asia_House_Singapore.jpg?p=medium600)
Animal Quarantine Service Uncovers Foreign National Attempting to Bring Livestock Products into Japan Illegally
TOKYO, May 15, 2024 /PRNewswire/ -- Last year, the Animal Quarantine Service (AQS) uncovered a foreign national who illegally brought meat such as sausages containing pork, which are prohibited from being imported toJapan from overseas, intoTokyo International Airport, and recently there was a ca...
2024-05-15 15:00
2051
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China
SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced that NEFECON®, a delayed rel...
2024-05-14 21:41
2362
Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong
A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal Immunization) * The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B disease through two seasons has been approved by Hong Kong Depa...
2024-05-08 16:14
1480
INTREPID Alliance Landscape of Promising Antivirals in Clinical Development Reveals Gaps in Global Defense Against Potential Future Pandemics
Detailed scientific analysis of antiviral pipeline identifies most promising clinical compounds aligned with 100 Days Mission global preparedness recommendations CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Building on its commitment to identify strengths and gaps in the R&D pipeline for ant...
2024-04-29 12:00
1344
Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa
SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year onApril 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger...
2024-04-26 12:39
1535
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...
2024-04-25 21:41
1507
Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19
Legacy coronavirus biochemistry was overlooked that governs spike protein toxicity, key morbidities, risk factors and therapeutic responses SALT LAKE CITY, April 22, 2024 /PRNewswire/ -- TrialSite News features a paper published today in Viruses (Basel), authored by an international team of resea...
2024-04-22 19:52
1347
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology
company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com
2024-04-19 13:17
2266
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology
company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com
2024-04-19 10:54
2279
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Vietnamese Organizations Institute of Gastroenterology and Hepatology and ...
2024-04-17 14:03
2067
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA
— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Indian Organizations Chennai Liver Foundation and FIND Receive the Grant t...
2024-04-17 11:22
1894
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
-- Gilead Awards US$4 Million Globally (Excluding the United States) Through The Gilead ALL4LIVER Grant -- -- World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee -- -- Hong Kong Liver Foundation and Hong Kong Liver Transplant Patients' ...
2024-04-15 12:22
1538
Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"
* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...
2024-04-08 20:00
2115
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant ...
2024-03-27 11:24
1804
CGTN: China advances battle against tuberculosis
BEIJING, March 25, 2024 /PRNewswire/ -- World Tuberculosis (TB) Day, which falls onMarch 24 every year, is designed to build public awareness that TB today remains a global public health problem that seriously endangers people's health. According to the World Health Organization's (WHO) Global T...
2024-03-25 15:12
1903
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today inManila, wi...
2024-03-25 10:00
935
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...
2024-03-25 08:04
1069
SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market
* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...
2024-03-21 13:24
2076
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
* A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis * Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries * The M72/AS01E vac...
2024-03-19 21:02
1586
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5608
